Detalhe da pesquisa
1.
Racial disparities in chronic lymphocytic leukemia/small lymphocytic lymphoma accounting for small molecule inhibitors: A real-world cohort analysis.
Am J Hematol
; 99(4): 780-784, 2024 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-38357757
2.
Acalabrutinib in treatment-naive chronic lymphocytic leukemia.
Blood
; 137(24): 3327-3338, 2021 06 17.
Artigo
em Inglês
| MEDLINE | ID: mdl-33786588
3.
Measurable residual disease does not preclude prolonged progression-free survival in CLL treated with ibrutinib.
Blood
; 138(26): 2810-2827, 2021 12 30.
Artigo
em Inglês
| MEDLINE | ID: mdl-34407545
4.
Phase 2 study of the safety and efficacy of umbralisib in patients with CLL who are intolerant to BTK or PI3Kδ inhibitor therapy.
Blood
; 137(20): 2817-2826, 2021 05 20.
Artigo
em Inglês
| MEDLINE | ID: mdl-33259589
5.
How Have Targeted Agents Changed the Treatment Landscape for Elderly Patients with CLL?
Curr Oncol Rep
; 24(12): 1705-1713, 2022 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-36334220
6.
Long-term follow-up of the RESONATE phase 3 trial of ibrutinib vs ofatumumab.
Blood
; 133(19): 2031-2042, 2019 05 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-30842083
7.
Acalabrutinib (ACP-196) in Relapsed Chronic Lymphocytic Leukemia.
N Engl J Med
; 374(4): 323-32, 2016 Jan 28.
Artigo
em Inglês
| MEDLINE | ID: mdl-26641137
8.
Targeting Bruton tyrosine kinase with ibrutinib in relapsed/refractory marginal zone lymphoma.
Blood
; 129(16): 2224-2232, 2017 04 20.
Artigo
em Inglês
| MEDLINE | ID: mdl-28167659
9.
Impact of ibrutinib dose adherence on therapeutic efficacy in patients with previously treated CLL/SLL.
Blood
; 129(19): 2612-2615, 2017 05 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-28373262
10.
Outcomes with ibrutinib by line of therapy and post-ibrutinib discontinuation in patients with chronic lymphocytic leukemia: Phase 3 analysis.
Am J Hematol
; 94(5): 554-562, 2019 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-30767298
11.
Final analysis from RESONATE: Up to six years of follow-up on ibrutinib in patients with previously treated chronic lymphocytic leukemia or small lymphocytic lymphoma.
Am J Hematol
; 94(12): 1353-1363, 2019 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-31512258
12.
Idelalisib addition has neutral to beneficial effects on quality of life in bendamustine/rituximab-treated patients: results of a phase 3, randomized, controlled trial.
Health Qual Life Outcomes
; 17(1): 173, 2019 Nov 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-31729982
13.
Idelalisib or placebo in combination with bendamustine and rituximab in patients with relapsed or refractory chronic lymphocytic leukaemia: interim results from a phase 3, randomised, double-blind, placebo-controlled trial.
Lancet Oncol
; 18(3): 297-311, 2017 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-28139405
14.
Resistance mechanisms for the Bruton's tyrosine kinase inhibitor ibrutinib.
N Engl J Med
; 370(24): 2286-94, 2014 Jun 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-24869598
15.
Idelalisib and rituximab in relapsed chronic lymphocytic leukemia.
N Engl J Med
; 370(11): 997-1007, 2014 Mar 13.
Artigo
em Inglês
| MEDLINE | ID: mdl-24450857
16.
Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia.
N Engl J Med
; 371(3): 213-23, 2014 Jul 17.
Artigo
em Inglês
| MEDLINE | ID: mdl-24881631
17.
The Bruton tyrosine kinase inhibitor ibrutinib with chemoimmunotherapy in patients with chronic lymphocytic leukemia.
Blood
; 125(19): 2915-22, 2015 May 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-25755291
18.
Long-term follow-up of MCL patients treated with single-agent ibrutinib: updated safety and efficacy results.
Blood
; 126(6): 739-45, 2015 Aug 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-26059948
19.
Clinical Practice Recommendations for Use of Allogeneic Hematopoietic Cell Transplantation in Chronic Lymphocytic Leukemia on Behalf of the Guidelines Committee of the American Society for Blood and Marrow Transplantation.
Biol Blood Marrow Transplant
; 22(12): 2117-2125, 2016 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-27660167
20.
Targeting BTK with ibrutinib in relapsed or refractory mantle-cell lymphoma.
N Engl J Med
; 369(6): 507-16, 2013 Aug 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-23782157